Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The CardioInsight™ Noninvasive 3D Mapping System is a non-invasive mapping system that collects chest ECG signals and combines these signals with CT scan data to produce and display simultaneous, bi-atrial and biventricular, 3-D cardiac maps. The mapping enables physicians to characterize abnormal rhythms of the heart.
Noninvasive — Map without Catheterization
Map anytime outside the EP lab throughout patient care pathway. Supports flexible patient management, procedural planning and lab use.
3-D, Simultaneous, Multi-Chamber Mapping
Captures and panoramically displays rhythms that span multiple chambers or vary in cycle length, such as atrial fibrillation (AF).
Insight with a Single Beat
Produce maps with one beat's worth of data for infrequent, unstable rhythms, such as ventricular tachycardia (VT) or specific supraventricular tachycardias (SVTs).
The CardioInsightTM system is based on the unique and patented Electrocardiographic Mapping (ECM) platform that combines body surface electrical data with heart-torso anatomical data to provide simultaneous, bi-atrial and biventricular 3-D maps of the heart's electrical activity.
The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, composite and phase maps.†
This system has been used on more than 1,600 patients in Europe and the United States, and it also has been featured in more than 120 peer reviewed manuscripts, abstracts and presentations.*
Note:
The CardioInsight system provides the unique opportunity to enable advanced cardiac mapping outside the EP lab.
Watch the animation below for an overview of the CardioInsight system.
Medtronic data on file
The clinical significance of solely utilizing phase maps to classify arrhythmia mechanisms has not been validated by clinical investigations.